Systematic review finds SGLT2 inhibitors improve survival and health outcomes in transthyretin cardiac amyloidosis, indicating a need for trial validation.
SGLT2 inhibitors, when used alongside disease-modifying agents, appear to improve survival and renal outcomes in patients with ATTR-CM. However, these findings are derived from observational studies with their inherent biases and must be interpreted with caution. High-quality randomised controlled trials are needed to confirm these associations and better define their clinical role in ATTR-CM.
No takes yet. Share an insight, caveat, or question.
Faheem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: